Health effects of CLA versus industrial trans fatty acids

Health effects of CLA versus industrial trans fatty acids - CLARINeT=CLA randomized intervention trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30632

Enrollment

Registered

2007-09-11

Start date

2007-09-26

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

indicatoren voor hart- en vaatziekten risk markers for cardiovascular disease

Interventions

It will be a double-blind randomized multiple cross-over trial with 3 treatments: • CLA • industrial trans fatty acids (as a positive control) • oleic acid (Cis 18:1, the monounsaturated fatty acid

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers aged 18 to 65 years

Exclusion criteria

Exclusion criteria: Subjects with chronic disease, such as diabetes or cardiovascular disease, and pregnant women will be excluded. Other exclusion criteria are abnormal cholesterol or triglyceride concentrations, use of cholesterol lowering medication, unusual dietary requirements, including high alcohol intakes and BMI > 30.

Design outcomes

Primary

Measure	Time frame
Blood: • Total and HDL cholesterol, Apo B, LDL cholesterol according to Friedewald • Triglycerides	—

Secondary

Measure	Time frame
Blood: • Insulin status markers, such as HOMA and revised QUICKY • Inflammatory markers, such as C-RP, IL-6, E-selectin, MCP-1, s-TNF-R1, s-TNF-R2, IFg • Fatty acid composition of cholesteryl esters [Zock, 1997] and erythrocytes as an objective measure of compliance with diets • Proteomics (DNA) Urine: iso-prostanes Blood Pressure and heart rate	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)